BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26874572)

  • 1. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Ibrahim DA; Abouhashem NS
    Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma.
    Wachter DL; Schlabrakowski A; Hoegel J; Kristiansen G; Hartmann A; Riener MO
    Am J Surg Pathol; 2011 Jun; 35(6):873-7. PubMed ID: 21566520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of S100P and IMP3 in the cytologic diagnosis of pancreatic adenocarcinoma.
    Ezzat NE; Tahoun NS; Ismail YM
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):229-234. PubMed ID: 27839709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.
    Levy M; Lin F; Xu H; Dhall D; Spaulding BO; Wang HL
    Hum Pathol; 2010 Sep; 41(9):1210-9. PubMed ID: 20382408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas.
    Yantiss RK; Cosar E; Fischer AH
    Acta Cytol; 2008; 52(2):133-8. PubMed ID: 18499984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
    Hassan R; Laszik ZG; Lerner M; Raffeld M; Postier R; Brackett D
    Am J Clin Pathol; 2005 Dec; 124(6):838-45. PubMed ID: 16416732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology.
    Kosarac O; Takei H; Zhai QJ; Schwartz MR; Mody DR
    Acta Cytol; 2011; 55(2):142-8. PubMed ID: 21325798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma.
    Hedegaard Jensen G; Mortensen MB; Klöppel G; Nielsen MFB; Nielsen O; Detlefsen S
    Pathol Res Pract; 2020 May; 216(5):152925. PubMed ID: 32273198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
    Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
    Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis.
    Watanabe H; Okada G; Ohtsubo K; Yamaguchi Y; Mouri H; Motoo Y; Wakabayashi T; Sawabu N
    Pancreas; 2005 May; 30(4):349-54. PubMed ID: 15841046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.
    Akashi T; Oimomi H; Nishiyama K; Nakashima M; Arita Y; Sumii T; Kimura T; Ito T; Nawata H; Watanabe T
    Pancreas; 2003 Jan; 26(1):49-55. PubMed ID: 12499917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor 2 binding protein 3 expression on endoscopic ultrasound guided fine needle aspiration specimens in pancreatic ductal adenocarcinoma.
    Tadic M; Stoos-Veic T; Kujundzic M; Turcic P; Aralica G; Boskoski I
    Eur J Gastroenterol Hepatol; 2020 Apr; 32(4):496-500. PubMed ID: 32109929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
    Lok T; Chen L; Lin F; Wang HL
    Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms.
    Glass JP; Parasher G; Arias-Pulido H; Donohue R; Prossnitz ER; Cerilli LA
    Int J Surg Pathol; 2011 Oct; 19(5):588-96. PubMed ID: 21632639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of IMP3 and p53 immunohistochemical staining in EUS-guided fine-needle aspiration for solid pancreatic tumors.
    Mikata R; Yasui S; Kishimoto T; Kouchi Y; Shingyoji A; Senoo J; Takahashi K; Nagashima H; Kusakabe Y; Ohyama H; Ohno I; Sugiyama H; Chiba T; Kato J; Kato N
    Sci Rep; 2021 Aug; 11(1):17257. PubMed ID: 34446759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
    Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
    Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic metastases of renal clear cell carcinoma: a clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas.
    Gnemmi V; Leroy X; Triboulet JP; Pruvot FR; Villers A; Leteurtre E; Buob D
    Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):157-62. PubMed ID: 24344503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
    Slosar M; Vohra P; Prasad M; Fischer A; Quinlan R; Khan A
    Endocr Pathol; 2009; 20(3):149-57. PubMed ID: 19449140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.